miR-6883 LNPs / SMURF-Therapeutics - LARVOL DELTA

Combination of CDK4/6 inhibitory and anti-hypoxia miRNA-6883 lipid nanoparticles with ferroptosis inducers or MEK inhibitors in preclinical breast and colorectal cancer models (AACR 2026) - "Accordingly, miR-6883 LNPs sensitized cells to doses of RSL3, erastin, or trametinib that were ineffective as monotherapies.ConclusionsOur data support the anti-hypoxia and antiproliferative activity of miR-6883, and provide a basis for combination therapies with ferroptosis inducers or MEKi. Future experiments will employ BC xenografts and assess long-term tumor growth inhibition of combination therapies."

Preclinical • Breast Cancer • Colorectal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • HIF1A • SMURF2